Moreover, prolonged treatment with G129R-hPRL at 100 μg/day resulted in a durable response, and reduced tumor weights by 50% compared to control, while in combination with paclitaxel produced more than a 90% inhibition (30). Here, PRLR is linked to neoplasm.